Vincenzo S. Gilberto

This paper demonstrates that inflammasome-inhibiting Nanoligomers reduce neuroinflammation and improve outcomes in an EAE mouse model of MS.

This paper shows that targeting neuroinflammation by down-regulating NF-κB and NLRP3 with SB_NI_112 protects against neurodegeneration in prion disease models.

The paper demonstrates that nanoligomers targeting NF-κB and IL-6 mitigate space-induced neurodegeneration in brain organoids, showing potential for neuroprotective countermeasures and drug screening.

This paper demonstrates that NI112, a brain-penetrant Nanoligomer targeting NF-κB and NLRP3, improves functional outcomes and reduces neuroinflammation in ALS and AD human organoid and mouse models.

This paper develops and tests two Nanoligomer-based therapies, CK1 and NI112, for IBD in mice, showing reduced disease severity and biomarker expression.

This paper evaluates the safety, pharmacokinetics, and biodistribution of an inflammasome-targeting Nanoligomer cocktail in small and large animals across multiple administration routes.